Clinical trials: Nonsmall Cell Lung Cancer Stage III
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
The primary objective is to document the safety of tecemotide (L-BLP25) phase III formulation in non-small cell lung cancer (NSCLC) subjects with unresectable Stage III disease.
- Trial name
- NCT00157196
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Best standard of care (BSC)
- Volunteers
- 22 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Stage III NSCLC
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
A Phase Ib, Open-label, Single-center study to assess the safety of cancer-immunotherapy induction with Tremelimumab and Durvalumab prior to Chemoradiotherapy in the treatment of locally advanced NSCLC.
- Trial name
- Induction (NCT04287894)
- Testing
- Durvalumab, Tremelimumab, Pemetrexed
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- The Netherlands Cancer Institute
Lung Cancer
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, carboplatin, and paclitaxel work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276588
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-small Cell Lung Carcinoma
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of Furmonertinib (AST2818) versus placebo in patients with stage II-IIIA non-small cell lung cancer (NSCLC) with centrally…
- Trial name
- FORWARD (NCT04853342)
- Testing
- Drug: Furmonertinib 80 mg
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Lung Cancer
Vinorelbine + Cisplatin or No Further Therapy in Non-small Cell Lung Cancer That Has Been Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if combination chemotherapy is more effective than no further treatment for non-small…
- Trial name
- NCT00002583
- Testing
- cisplatin, vinorelbine ditartrate
- Where
- 155 sites in United States, Canada
- Volunteers
- 482 people
- Sponsor
- NCIC Clinical Trials Group
Lung Cancer
S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00288054
- Testing
- cetuximab, docetaxel, radiation therapy
- Where
- 77 sites in United States
- Volunteers
- 24 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Thoracoscopy in Patients With Stage IIIA Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures such as thoracoscopy may help to measure a patient's response to previous treatment. PURPOSE: Diagnostic trial to determine the accuracy of thoracoscopy in patients who have stage IIIA non-small…
- Trial name
- NCT00003566
- Testing
- videothoracoscopy
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 75 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Lung Cancer
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01041781
- Testing
- carboplatin, celecoxib, gemcitabine hydrochloride
- Where
- 400 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer (NSCLC)
Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients
This study aims to investigate the expression of Melanoma-associated antigen 3 (MAGE-A3), Melanoma-associated antigen C2 (MAGE-C2), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), L antigen family member 1 (LAGE-1)…
- Trial name
- NCT01837511
- Testing
- Data acquisition and analysis
- Where
- 3 sites in Singapore, South Korea
- Volunteers
- 377 people
- Sponsor
- GlaxoSmithKline
Lung Cancer
ERCC1 Targeted Trial
Lung cancer is the leading cause of cancer death in the UK, leading to 34 000 deaths each year (22% of cancer deaths). Non-small cell lung cancer (NSCLC) is the most common histology, accounting for approximately 80% of cases and…
- Trial name
- ET (NCT00801736)
- Testing
- Cisplatin, Paclitaxel
- Where
- United Kingdom
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- University College, London
Lung Cancer
Radiation Therapy, Chemotherapy, and Bevacizumab in Treating Patients With Recurrent, Unresectable or Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by…
- Trial name
- NCT00334763
- Testing
- bevacizumab, carboplatin, chemoprotection
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Northwestern University
Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
This randomized phase III trial studies carboplatin and paclitaxel to compare how well they work with or without bevacizumab and/or cetuximab in treating patients with stage IV or non-small cell lung cancer that has returned…
- Conditions
- Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma
- Trial name
- NCT00946712
- Testing
- Bevacizumab, Carboplatin, Cetuximab
- Where
- 798 sites in United States, Mexico
- Volunteers
- 1,333 people
- Sponsor
- SWOG Cancer Research Network
Unresectable Stage III NSCLC
Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC
The chemoradiotherapy (CCRT) is still a standard treatment for the unresectabl stage III NSCLC.However, prognosis following this treatment is generally poor, with 5-year survival of 15-20%.
- Trial name
- R-helper (NCT04161352)
- Volunteers
- 500 people
- Sponsor
- Zhejiang Cancer Hospital
Lung Neoplasms, Neoplasm Metastasis
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
This phase I study proposes the use of systemic thiosulfate rescue to allow supradose intra-arterial cisplatin delivery to lung tumors.
- Trial name
- NCT01114958
- Testing
- Cisplatin, Thiosulfate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, San Diego
Bronchial Cancer
Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer
The aim of this study is to evaluate the real-life efficacy of durvalumab treatment in consolidation after radio-chemotherapy.
- Trial name
- DURVABREIZH (NCT06564870)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Brest
Breast Cancer, Lung Cancer
HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer
RATIONALE: Vaccines made from the HER2/neu antigen may make the body build an immune response and kill tumor cells. Colony-stimulating factors such as GM-CSF increase the number of immune cells found in bone marrow or peripheral…
- Conditions
- Breast Cancer, Lung Cancer, Ovarian Cancer
- Trial name
- NCT00003002
- Testing
- HER-2/neu peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Washington
Stage III NSCLC
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
A Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC. Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR…
- Trial name
- NCT07264647
- Testing
- Tislelizumab, surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines, Chemoradiotherapy
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione Ricerca Traslazionale
Lung Cancer
Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028938
- Testing
- epoetin alfa, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Non-Small Cell Lung Cancer
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in…
- Trial name
- NCT02486718
- Testing
- Atezolizumab, Cisplatin, Vinorelbine
- Where
- 216 sites in United States, Australia and 20 more
- Volunteers
- 1,280 people
- Sponsor
- Hoffmann-La Roche